Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1

Conditions

Ovarian Neoplasms 34Uterine Cervical Neoplasms 24Fallopian Tube Neoplasms 18Endometrial Neoplasms 16Neoplasm Metastasis 10Lung Neoplasms 9Pancreatic Neoplasms 8Stomach Neoplasms 7Colorectal Neoplasms 7Carcinoma, Transitional Cell 7Breast Neoplasms 7Melanoma 6Carcinoma, Renal Cell 6Prostatic Neoplasms 5Esophageal Neoplasms 5Carcinosarcoma 5Carcinoma, Hepatocellular 5Vaginal Neoplasms 4Triple Negative Breast Neoplasms 4Thyroid Neoplasms 4Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Testicular Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Multiple Myeloma 3Cholangiocarcinoma 3Brain Neoplasms 3Vulvar Neoplasms 2

Interventions

Taxes 2Paclitaxel 2Magnetic Resonance Spectroscopy 2olaparib 1liposomal doxorubicin 1copanlisib 1Topotecan 1Specimen Handling 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Bevacizumab 1ASTX-660 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Platinum-Refractory Fallopian Tube Carcinoma × Magnetic Resonance Spectroscopy × Gynecologic × Clear all
NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

NCT05295589 2023-09-26

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gynecologic

Platinum-Refractory Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡